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AbstrAct
Objective To investigate the effectiveness of different 
treatments for gestational diabetes mellitus (GDM).
Design Systematic review, meta-analysis and network 
meta-analysis.
Methods Data sources were searched up to July 2016 
and included MEDLINE and Embase. Randomised trials 
comparing treatments for GDM (packages of care (dietary 
and lifestyle interventions with pharmacological treatments 
as required), insulin, metformin, glibenclamide (glyburide)) 
were selected by two authors and double checked for 
accuracy. Outcomes included large for gestational age, 
shoulder dystocia, neonatal hypoglycaemia, caesarean 
section and pre-eclampsia. We pooled data using random-
effects meta-analyses and used Bayesian network meta-
analysis to compare pharmacological treatments (ie, 
including treatments not directly compared within a trial).
Results Forty-two trials were included, the reporting of 
which was generally poor with unclear or high risk of bias. 
Packages of care varied in their composition and reduced 
the risk of most adverse perinatal outcomes compared 
with routine care (eg, large for gestational age: relative 
risk0.58 (95% CI 0.49 to 0.68; I2=0%; trials 8; participants 
3462). Network meta-analyses suggest that metformin 
had the highest probability of being the most effective 
treatment in reducing the risk of most outcomes compared 
with insulin or glibenclamide.
Conclusions Evidence shows that packages of care are 
effective in reducing the risk of most adverse perinatal 
outcomes. However, trials often include few women, are 
poorly reported with unclear or high risk of bias and report 
few outcomes. The contribution of each treatment within 
the packages of care remains unclear. Large well-designed 
and well-conducted trials are urgently needed.
Trial registration number PROSPERO CRD42013004608.
IntroductIon
Treatment of gestational diabetes mellitus 
(GDM) aims to reduce hyperglycaemia and 
in turn reduce the risk of adverse perinatal 
outcomes including large for gestational 
age (LGA), macrosomia, shoulder dystocia, 
neonatal hypoglycaemia and the need for 
caesarean section. Diet modification is often 
used as first-line treatment, and if partly or wholly 
unsuccessful or where women have substantially 
elevated glucose at diagnosis, pharmacological 
treatments (metformin, glibenclamide (glybu-
ride) and/or insulin) are offered.
Previous systematic reviews have inves-
tigated the effectiveness of treatments for 
GDM.1–15 Although results from these reviews 
generally indicate that treatment reduces 
the risk of adverse perinatal outcomes, the 
searches have variable inclusion criteria 
and were undertaken between 20091 5 and 
20142–4 6–8 10 11 16 16 with three reviews with 
searches in 2015,9 14 15 and since then, several 
trials have been published and recommended 
criteria for GDM diagnosis have changed. 
Some reviews have included observational 
studies, and most do not review all treat-
ments, with the exception of the Cochrane 
treatments review1 (which is now out of date 
and has been divided for future updates) 
and the UK National Institute for Health 
and Care Excellence (NICE) guideline.16 
Consequently, most previous reviews do not 
provide an assessment of all available treat-
ments, and most have not used a network 
meta-analysis to determine the most effective 
pharmacological treatment across all alterna-
tives included in any randomised controlled 
trial (RCT).
The aim of this study was to systematically 
review and, where appropriate, pool all results 
from RCTs of the effect of any treatment on 
GDM and to determine which treatment is 
the most effective.
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Strengths and limitations of this study
 ► This systematic review evaluates available 
interventions for the treatment of gestational 
hyperglycaemia and includes a network meta-
analysis comparing all pharmacological treatments 
for gestational diabetes.
 ► A large number of trials conducted in varied 
populations have been included.
 ► For some comparisons, the numbers of trials 
included were few, and outcomes reported were 
few.
 ► Trial quality was generally poor with subsequent 
high or unclear risk of bias.
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Figure 1 Search process.
Methods
We conducted a systematic review, meta-analysis and 
network meta-analysis to evaluate whether treatments for 
GDM reduce the risks of adverse perinatal outcomes and 
to compare the effectiveness of these treatments.
This review and meta-analysis was conducted in accor-
dance with Cochrane systematic reviews17 and the Centre 
for Reviews and Dissemination recommendations18; we 
have reported our findings following the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) reporting guidelines (see online supplemen-
tary research checklist).19 This review forms part of a 
larger health technology assessment report of the diag-
nosis and management of GDM.20
Patient involvement
The outcomes we included were from the Cochrane Preg-
nancy and Childbirth Group’s standardised outcomes for 
reviews of diabetes in pregnancy. Women who had experi-
enced or had the potential to experience GDM contribute 
to the design and appraisal of this group’s methods and 
reviews and therefore have influenced the design of this 
review and outcomes examined.21
search methods
The search strategies were designed to identify records 
of RCTs of treatment of women with GDM, added to 
search sources since the search date (July 2011, trials 
awaiting classification) of the Cochrane ‘treatments for 
GDM’ review.1 The bibliographic databases searched 
were MEDLINE and MEDLINE in Process, Embase and 
the Cochrane Central Register of Controlled Trials. Strat-
egies were not restricted by language and were developed 
using a combination of subject indexing terms and free 
text search terms in the title and abstract fields. Searches 
were first conducted in September 2013 and updated 
in October 2014 and 6 July 2016, using the same search 
strategies. Information on studies in progress was sought 
by searching relevant trial registers including  Clinical-
Trials. gov.
We also searched previously published systematic reviews 
to ensure any eligible RCTs from these were included in 
our review if eligible.2–9 In addition, we checked the refer-
ences of included journal articles. An example of search 
terms for MEDLINE is included in online supplementary 
file 1.
study selection
Inclusion and exclusion criteria
We included RCTs in which women with diagnosed GDM 
or impaired glucose tolerance (IGT) (using any defini-
tion) were randomised to a treatment designed to lower 
blood glucose (pharmacological or dietary modification) 
compared with routine antenatal care (however defined 
by the trial) or another treatment. Trials including women 
with pre-existing diabetes were excluded. Trials had to 
report effects on adverse perinatal outcomes. Included 
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outcomes (defined in any way by the trials) were gesta-
tional age at birth, birth weight (BW), macrosomia, LGA, 
shoulder dystocia, preterm birth (less than 37 weeks gesta-
tion), neonatal hypoglycaemia, admission to neonatal 
intensive care unit (NICU), caesarean section (elective 
or emergency), pre-eclampsia, pregnancy-induced hyper-
tension (PIH), induction of labour, instrumental birth 
(forceps or ventouse), Apgar score at 5 min and negative 
treatment effects (eg, gastrointestinal upset, well-being). 
Data on side effects and quality of life measures were 
also examined. Conference abstracts and letters to jour-
nals were eligible for inclusion if they reported sufficient 
outcome data.
data extraction and risk of bias assessment
Title and abstract screening and then full-text screening 
were performed by two reviewers (DF, MS, MB or SG) 
with disagreements resolved by consensus or by the 
third reviewer. The risk of bias of the included trials was 
assessed using the Cochrane risk of bias tool,22 which 
considers sequence generation, allocation concealment, 
blinding of participants and medical staff to treatment 
allocation, blinding of assessors, loss to follow-up, selec-
tive reporting of outcomes and other sources of bias. 
Each criterion was classified as being at low or high risk of 
bias or unclear. Two reviewers independently assessed all 
criteria (DF, MS or SG).
statistical analysis
Trials were divided into categories according to 
the following included treatments: (1) insulin versus 
metformin; (2) insulin versus glibenclamide (glybu-
ride); (3) metformin versus glibenclamide; (4) packages 
of care: diet or dietary advice with or without exercise 
or glucose monitoring, with or without supplemental 
metformin, glibenclamide or insulin, compared with 
routine antenatal care; and (5) comparisons of different 
dietary modifications.
For dichotomous outcomes, the relative risk (RR) 
comparing each group, with its 95% CI, was calculated 
from the numbers of outcome events in each randomised 
group and the number randomised to each group. For 
continuous outcomes, the difference in means between 
groups was calculated from the mean and SD of the 
outcome. For each outcome and within each of the treat-
ment categories, RRs or differences in means were pooled 
in random-effects DerSimonian-Laird meta-analyses.23 
Heterogeneity was assessed using I2. 24 Analyses were 
performed to investigate differences in risk of outcomes 
across varying degrees of hyperglycaemia (defined by a 
positive/negative GDM screening and diagnostic test). 
Because of the large number of treatments and outcome 
comparisons, pooled estimates only are presented in the 
main paper. Tests for publication bias were considered, 
but not performed, because there were insufficient trials 
in any meta-analysis for such tests to be reliable.
We also conducted a network meta-analysis to combine 
information across multiple treatments simultaneously; 
this combines direct and indirect data to improve the esti-
mation of the effectiveness of treatments and specifically 
to try to estimate which is the most effective of a number 
of different treatment options.25–28 Analyses were under-
taken for each dichotomous outcome using a Bayesian 
approach, based on the models originally created by Lu 
and Ades,29 using the OpenBUGS30 software. The model 
has a ‘binominal-normal’ structure; that is, events were 
assumed to follow a binomial distribution, with log odds 
and random effects being normally distributed. Vague 
normal priors (mean 0, variance 10 000) were used 
except for heterogeneity, where an inverse-gamma (0.1, 
0.1) distribution was used. The model fit and consistency 
were assessed by comparing the results to the meta-anal-
yses comparing each treatment directly.
Each model generated a comparison between treat-
ments, expressed as an OR and as a percentage indicating 
the probability that the treatment was the best treatment 
to reduce the incidence of the adverse outcome. ORs 
were used to ensure model stability because log ORs more 
closely follow a normal distribution than RRs. The proba-
bilities of being most effective treatment were calculated 
from the posterior odds as part of the Bayesian model 
developed by Lu and Ades.29 This approach was not 
possible for continuously measured outcomes and so was 
not undertaken for gestational age, BW and Apgar score. 
As there were no trials comparing diet modification to 
pharmacological treatments, diet modification could not 
be included in the network meta-analyses.
results
details of included and excluded trials
A total of 12 234 citations were identified by the orig-
inal and the two update searches. These citations were 
combined with three additional citations identified by 
previous systematic reviews conducted prior to our first 
searches.1–5 Following de-duplication and inclusion of 
additional records, 6437 citations were reviewed. Of 
these, 214 were judged potentially eligible based on title 
and abstract. After obtaining the full-text publications 
and assessing eligibility, 42 trials were included, and 35 
of these were combined in at least one meta-analysis 
(figure 1).
Having extracted data from the RCTs assessing packages 
of care and dietary intervention comparisons (table 1), 
we decided that it was not appropriate to pool results 
from trials comparing dissimilar dietary modification 
interventions (table 1). Packages of care included various 
combinations of interventions; however, all packages of 
care compared with routine care trial results were pooled 
in meta-analyses.
We included eight publications not included in any 
previous published review. One compared metformin 
and insulin31; one, glibenclamide and insulin32; four, 
packages of care with routine care33–36; and two 
compared different dietary modification interven-
tions.37 38 Six of these trials were reported after the 
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search dates of the previous reviews and were published 
in 2014 or 2015; the remaining two trials (dietary modi-
fication interventions or packages of care) did not fulfil 
other review’s inclusion criteria. Few trials reported side 
effects or measures of participant satisfaction or well-
being.
Trials generally included women with GDM diagnosed 
following a 75 or 100 g oral glucose tolerance test (OGTT) 
using a variety of international39–41 and locally42 43 recom-
mended thresholds; although some included women with 
‘mild or borderline’ GDM (positive oral glucose chal-
lenge test (OGCT), negative OGTT) and others included 
women with IGT, current diagnostic criteria16 44, however, 
may now consider these women as having GDM rather 
than a separate and milder condition.
Quality – risk of bias assessment
Overall, reporting of and many aspects of trial quality were 
poor with the result that risk of bias was generally unclear 
or high (online supplementary table 1). The rando-
misation procedure and group allocation were rarely 
described, although all trials reported that participants 
were ‘randomised’. Blinding of participants, medical 
staff and outcome assessors was generally not reported, 
but as most trials include some additional intervention 
above routine care such as diet advice or a pharmaco-
logical treatment, it is probable that participants and 
most clinicians could not be blinded, although outcome 
assessment could have been. Most trials had reasonably 
complete outcome data and loss to follow-up was low, 
although for some trials, analysis was not conducted on 
an intention-to-treat basis (so the analysis did not include 
all women randomised). Selective reporting was assessed 
as minimal, as the majority of trials presented results 
for all prespecified outcomes (the possibility that some 
trials collected data on outcomes but did not report them 
cannot be ruled out however).
Generally, women were eligible for inclusion in trials 
evaluating pharmacological treatments if they were 
unable to achieve adequate glycaemic control with dietary 
and lifestyle management. Therefore, there is the possi-
bility that those included may have had more severe or 
refractory hyperglycaemia or may adhere less well to life-
style interventions than those women who did not require 
pharmacological treatments to control hyperglycaemia. 
The specific criteria for the addition of supplemental 
insulin in trials were often not reported, although some 
trials did report that supplemental insulin was prescribed 
if ‘glycaemic control was not achieved by participants’. It 
is probable that thresholds for what is defined as ‘good’ 
control differed between trial centres (if multisite) and 
trials.
Packages of care and dietary modification trials
Twelve trials evaluated a package of care (a combination 
of treatments starting with dietary modification and/or 
exercise and/or monitoring and/or supplemental phar-
macological treatments) (table 1)33–36 45–52 compared with 
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Figure 2 Forest plots for treatment comparisons and perinatal outcomes. (A) Packages of care (starting with dietary 
modification) versus routine care: dichotomous outcomes. (B) Packages of care (starting with dietary modification) versus 
routine care: continuous outcomes. (C) Metformin versus insulin: dichotomous outcomes. (D) Metformin versus insulin: 
continuous outcomes. (E) Glibenclamide versus insulin: dichotomous outcomes. (F) Glibenclamide versus insulin: continuous 
outcomes. (G) Glibenclamide versus metformin: dichotomous outcomes. (H) Glibenclamide versus metformin: continuous 
outcomes.
routine care. Data from these 12 trials are combined in at 
least one meta-analysis (figure 2A,B).
Seven trials37 38 53–57 evaluated a variety of dietary 
modifications and compared them to other dietary 
modifications (table 1). The composition of each dietary 
modification was generally well reported; however, the 
interventions and comparisons were too diverse to allow 
pooling of data. There was no evidence that one type of 
dietary modification was superior over another, although 
trials included few women (online supplementary figures 
1 and 2). None of these seven trials reported side effects 
or quality of life measures.
The composition of the dietary modification was 
poorly reported in the ‘packages of care’ trials (the 12 
trials included in the meta-analyses). Overall (in all pack-
ages of care and dietary modification trials), 10 out of 
19 trials reported that insulin was provided if required; 
in one trial, insulin was only provided if needed in the 
intervention group; and for the remainder, it was unclear 
or not reported if supplemental insulin was provided. 
The screening and diagnostic tests, criteria and glucose 
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thresholds used to define GDM (and included/exclude 
women in the trials) varied across the trials (table 1). For 
the meta-analysis, the varying forms of dietary modifi-
cation and/or pharmacological treatment use were not 
examined.
Packages of care (starting with dietary modification 
and possibly including monitoring and pharmacolog-
ical interventions) reduced the risk of shoulder dystocia 
by 60%, LGA and macrosomia by around 50%, pre-ec-
lampsia by 20% and the incidence of caesarean section by 
10% compared with routine care (figure 2A), although 
for pre-eclampsia and caesarean section, the CIs included 
the null value. BW was reduced by approximately 110 g in 
the packages of care compared with routine care group 
(figure 2B). The degree of heterogeneity (I2) varied by 
outcome from 0% to 77%. No ‘packages of care trial’ 
reported side effects; two trials reported quality of life 
scores47 48 indicating higher (better) quality of life scores 
for women in the intervention compared with the routine 
care group.
trials comparing metformin with insulin
Eleven trials compared metformin with insulin 
(table 2).31 43 58–66 However, most trials reported supple-
mental insulin use in the metformin group with the 
exception of two trials.31 64 The risk of most outcomes, 
including LGA, macrosomia, NICU admission, neonatal 
hypoglycaemia, pre-eclampsia, PIH and induction of 
labour, was lower in those randomised to metformin 
rather than insulin; instrumental delivery was greater in 
those randomised to insulin (figure 2C). BW, gestational 
age and Apgar score as continuous measurements did not 
differ notably between the two treatments (figure 2D). 
Six trials reported the proportion of women with 
metformin-associated gastrointestinal upset (between 
4% and 46%).58–60 63 65 66 No trial reported quality of life 
measures.
trials comparing glibenclamide (glyburide) with insulin
Nine trials compared glibenclamide with insulin 
(table 3).32 67–74 Figure 2E shows the RRs of dichotomous 
outcomes, suggesting that insulin may be relatively more 
effective than glibenclamide in reducing the risk of several 
adverse outcomes; CIs are wide and include the null 
value however. There was no difference between insulin 
and glibenclamide for continuous outcomes (figure 2F). 
One trial reported that glibenclamide was associated with 
side effects in 3/48 (6%) of women.72 No trial reported 
quality of life measures.
trials comparing glibenclamide (glyburide) with metformin
Only three trials were identified that directly compared 
glibenclamide with metformin, and these were rela-
tively small trials including between 149 and 200 women 
(table 4).75–77 Figure 2G shows the risk of dichotomous, 
and figure 2H shows continuous outcomes. These suggest 
that metformin is more effective at reducing risk of LGA 
and possibly macrosomia. However, for several of the 
outcomes (eg, LGA), only data from one of these trials 
are available; it is therefore not possible to make robust 
conclusions about the relative benefits of metformin and 
glibenclamide from these direct comparisons. No trials 
reported side effects or quality of life measures.
network meta-analysis comparing glibenclamide 
(glyburide), insulin and metformin
Figure 3 shows the relationship of treatment compar-
isons, and table 5 shows the estimated probability of 
a treatment being the most effective at reducing the 
risk of each dichotomous outcome. Only dichotomous 
outcomes reported in at least two glibenclamide trials 
(either in comparison to insulin or metformin) were 
included in these analyses to ensure that there were suffi-
cient trials (and participants) included. When all three 
treatments are jointly compared, these analyses suggest 
that, for all outcomes, with the exception of caesarean 
section, metformin is most likely to be the most effective 
treatment, with its probability of being most effective in 
reducing risk being 96.3%, 94.0%, 92.8%, 84.0% and 
61.2%, respectively, for neonatal hypoglycaemia, macro-
somia, LGA, pre-eclampsia and admission to NICU (the 
probability of being most effective for reducing risk of 
caesarean section was 9.7% for metformin, glibenclamide 
was most likely to be most effective at reducing the risk of 
caesarean section (79.9%)). The results of the network 
meta-analysis (figure 4) are consistent with the direct 
comparisons between treatments shown in figure 2A–H, 
suggesting that metformin is more effective than insulin 
or glibenclamide at reducing the majority of adverse 
outcomes. However, many of these comparisons are 
based on small numbers and have wide CIs that some-
times include the null value.
dIscussIon
The key finding of our review is that, despite under-
standing of hyperglycaemia/GDM and its relationship 
to adverse perinatal outcomes having existed for at least 
seven decades78 and 42 RCTs completed on its treatment, 
trials are still being conducted that are of limited size 
and of poor quality (with subsequent unclear or high 
risk of bias), and therefore, which treatment is the most 
effective remains unclear. Given the changing character-
istics of the population and the lower fasting diagnostic 
threshold (compared with previous criteria)40 recom-
mended by the International Association of Diabetes and 
Pregnancy Study Groups (IADPSG)44 and UK NICE,16 
it is important to understand how treatments affect 
outcomes for these women. Trials do not always report 
GDM diagnostic criteria clearly, and this is important 
considering the potential influence on GDM popula-
tion size and the magnitude of effect.16 44 Our detailed 
review, including only evidence from RCTs, provides 
some support for a ‘step up approach’ in the treatment 
of hyperglycaemia, from dietary interventions, through 
addition of metformin (in preference to glibenclamide 
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(glyburide)) through addition of insulin. Considering 
that hyperglycaemia in pregnancy has various causes and 
many women will be treated successfully with diet and life-
style interventions (because lower thresholds lead to less 
severe hyperglycaemia being classified as GDM), using 
an integrated individual approach to its management is 
likely to work best, although trials and reviews continue 
to be conducted that pay little attention to the influence 
of non-pharmacological treatments for GDM and often 
do not provide information on the severity of hypergly-
caemia in treatment groups.
We have taken a pragmatic approach to evaluating 
the many trials examining treatment packages of care 
for women diagnosed with hyperglycaemia/GDM so 
that our results will be generalisable to most clinical 
situations. Several previous reviews have focused exclu-
sively on pharmacological treatments2 6 8 9 12–15; however, 
others have also suggested that packages of care with a 
‘step up’ approach are the most effective.1 3–5 The severity 
of hyperglycaemia may influence the effectiveness of a 
treatment; however, many trials do not report treatment 
subgroup baseline glycaemic levels (eg, diet only, diet 
and metformin or insulin, or metformin with supplemen-
tary insulin).34–36 45 47 48 51 62–65 79 For those trials reporting 
baseline glycaemic levels by treatment subgroup, there is 
inconsistency, with some reporting significant differences 
between groups59 66 and others reporting no differ-
ence.43 58 60 Understanding of treatment effects would 
be improved if baseline OGTT levels were presented by 
treatment subgroup in future trials.
The number of trials and women included in previous 
reviews varies. One recent review had broadly similar 
inclusion criteria to ours, comparing any package of care 
for the treatment of GDM with no treatment (routine 
care) and included five trials with 2643 women.3 Our 
review includes all these trials, plus a further seven 
(included in the meta-analysis) increasing the number 
of women to 4512 and indicating that RCTs in this 
area continue to be conducted, but not with the size or 
quality that allows us to have a robust evidence base for 
the treatment of GDM in a contemporary population. 
Pooled estimates are generally consistent across reviews 
of packages of care irrespective of the number of trials 
included because estimates are driven in all reviews by 
the two largest, which are also the highest quality trials; 
however, these trials were conducted in populations using 
diagnostic criteria that would provide populations with 
more severe hyperglycaemia (and therefore the poten-
tial for a larger effect size).47 50 For example, our analysis 
shows the risk of macrosomia is halved when a package 
of care is provided compared with routine care (11 trials, 
RR 0.49, 95% CI 0.39 to 0.62), confirming estimates from 
the most recent previous review (RR 0.50, 95% CI 0.35 to 
0.71).3 These two large and well-conducted RCTs were 
published in 2005 and 2009,47 50 and since then, several 
smaller and poorer quality trials have been published. 
These two previous large well-conducted trials cannot 
provide precise estimates of effect on the wider range of 
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adverse outcomes and for women diagnosed using more 
recently recommended criteria. Hence, we feel that it is 
important to place a moratorium on further small RCTs 
in this area and that funders should consider commis-
sioning a multicentre large-scale RCT with adequate 
power to determine the effect and cost-effectiveness 
of different packages of care on adverse outcomes in 
women with GDM.
The evidence to support metformin use, although 
encouraging, has certain weaknesses. First, although 
there is a general ‘trend’ in favour of metformin use over 
insulin and glibenclamide (glyburide), CIs are wide, in 
both the direct and network meta-analysis comparing 
each two-way treatment effect. Second, the reporting of 
trial methods was generally poor with ‘unclear or high risk 
of bias’, and many trials included relatively few women 
and reported few outcomes. Third, in most trials directly 
comparing metformin with insulin, women receiving 
metformin were also given supplemental insulin ‘if 
required’; in one of the largest trials, this equated to 46% 
of the metformin group.59 Therefore, our results more 
appropriately relate to metformin’s greater effectiveness 
as a first-line treatment for GDM rather than a standalone 
treatment compared with insulin.
In addition to being an effective first-line pharmacolog-
ical treatment for GDM, metformin may also be preferred 
by women as it is administered orally and can be stored 
at room temperature, compared with insulin that 
requires subcutaneous injection and refrigerated storage. 
Metformin is sometimes associated with gastrointestinal 
upset, which may affect compliance and quality of life.
Few trials have reported side effects or measures of 
participant satisfaction or well-being, all important 
outcomes that have the potential to impact health and 
therefore should be evaluated. Recent guidance16 44 
recommends lower glucose thresholds compared with 
those previously recommended to diagnose GDM39 40 (and 
used in the included trials). Therefore, it is possible that 
a greater proportion of women diagnosed with GDM will 
require only diet modification or less ‘intensive’ manage-
ment compared with those previously diagnosed with 
GDM because their hyperglycaemia is less severe. There 
is a continuum of increasing risk of adverse outcomes 
across the spectrum of glucose however80 81; therefore, 
interventions to reduce hyperglycaemia even at lower 
glucose levels are likely to improve outcomes, but this 
needs confirming by large well-designed RCTs.
strengths and limitations
This systematic review and meta-analysis includes a large 
number of trials with varied populations and examines 
the effectiveness of treatment packages and diets as well 
as individual pharmacological treatments for reducing 
the risk of adverse perinatal outcomes.
For some comparisons, trials and numbers of women 
were few, as were outcomes reported. Trial quality was 
generally poor with subsequent high or unclear risk of bias. 
GDM diagnostic criteria varied across trials, and recently 
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Figure 3 Network meta-analysis, relationship of treatment 
comparisons.
Table 5 Estimated probability (%) of a treatment being 
the most effective in reducing the risk of a dichotomous 
outcome
Outcome
Treatment
Insulin Metformin
Glibenclamide 
(glyburide)
Large for gestational 
age 7.1 92.8 0.1
Macrosomia 5.6 94.0 0.3
Neonatal intensive 
care admission 0.5 61.2 38.3
Neonatal 
hypoglycaemia 3.3 96.3 0.4
Caesarean section 10.4 9.7 79.9
Pre-eclampsia 4.8 84.0 11.2
Figure 4 Network meta-analysis comparing metformin, 
glibenclamide and insulin. First better, treatment listed first 
in the outcome column is superior; second better, treatment 
listed second in the outcome column is superior. C-section, 
caesarean section; LGA, large for gestational age; NICU, 
neonatal intensive care unit.
recommended thresholds are lower now compared with 
when most included trials were conducted.
Lower glucose threshold criteria recommended by 
the International Association of Diabetes and Pregnancy 
Study Groups44 and subsequently endorsed by the WHO82 
aim to identify offspring at risk of obesity through its 
association with LGA (birth weight >90th percentile), 
cord C-peptide >90th percentile and percentage body 
fat >90th percentile. However, there are no trials that 
have used these criteria, and the classification of less 
severe hyperglycaemia when lower glucose thresholds 
are used to diagnose GDM may reduce the magnitude of 
the effect of interventions, compared with those reported 
by earlier trials using higher glucose thresholds. There 
has also been no longer term follow-up conducted to 
evaluate the treatment of GDM and the effects on risk of 
offspring outcomes. Importantly, few of the trials that we 
reviewed had reported side effects or measures of partici-
pant satisfaction or well-being.
Implications for practice
This review provides reassurance that a package of care 
where a ‘step up’ approach of first providing dietary and 
lifestyle advice, then adding supplementary metformin 
or insulin if glucose levels are not adequately controlled, 
is a reasonable and effective approach compared with 
providing just routine antenatal care, particularly with 
regard to reducing the risk of LGA. However, it has also 
highlighted the general poor quality of recent small RCTs 
that do not improve the evidence base but subject women 
with GDM to unnecessary ‘experimentation’ and are a cost 
to society.
Metformin seems to be an effective alternative to insulin, 
if diet modification inadequately controls hyperglycaemia; 
however, supplemental insulin may be required in up to 
50% of women.59 There is a need to cease further small 
RCTs in this area and conduct large well-designed RCTs 
that clarify the most effective treatment across a range of 
outcomes, including those that are likely to be important 
to women such as quality of life measurements and those 
identified by the Cochrane Pregnancy and Childbirth 
Group as being essential for trials and reviews of diabetes in 
pregnancy. These should be incorporated into current diag-
nostic criteria and ideally look at longer term outcomes in 
mothers and offspring.
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